Skip to Main Content

When Michael Klichinsky was rotating through University of Pennsylvania hospitals as a pharmacy student more than eight years ago, he asked a lot of cancer specialists a lot of questions — many of which got the same answer.

“Folks that I was working with would say something like ‘Oh, don’t worry about that. There’s a guy upstairs that’s working on engineered T cells that will kill the cancer soon anyway.’” That “guy upstairs” was CAR-T pioneer Carl June — who now sits on the scientific advisory board of Klichinsky’s cell therapy startup, Carisma Therapeutics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!